AGTC Announces Completion of Enrollment in All Adult Dose Groups of Its Ongoing Phase 1/2 Clinical Trials in Patients With Achromatopsia
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials... Read More
AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of Its Ongoing Phase 1/2 Clinical Trial in Patients With X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials... Read More
AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials... Read More
AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials... Read More
AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials... Read More
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
UF startup Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the... Read More
AGTC to Present at Upcoming Conferences
UF startup Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the... Read More
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
UF startup and UF Innovate│Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated... Read More
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment... Read More
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment... Read More
